SEHK:2005Pharmaceuticals
How Investors May Respond To SSY Group (SEHK:2005) China Drug Approvals
SSY Group secured past approvals from China’s National Medical Products Administration for Letermovir Injection and Diltiazem Hydrochloride Tablets, expanding its perioperative and cardiovascular treatment range using its existing strength in intravenous infusions.
The combination of a CMV prevention therapy for transplant patients and a chronic cardiovascular medicine deepens SSY Group’s presence in high-acuity hospital settings, which can influence capacity utilization and product mix...